Tarsus Pharmaceuticals, Inc.
TARS
株式のランク
#4581
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm... Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions. Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.
株価
$72.08
時価総額
$3.37B
変化（1日）
1.48%
変化（1年）
1.78%
国
US
取引 Tarsus Pharmaceuticals, Inc. (TARS)
カテゴリー
Healthcare
Tarsus Pharmaceuticals, Inc.（TARS）の収益
Jun 2026 時点の収益 TTM: $606.33M
Tarsus Pharmaceuticals, Inc. の最新の財務報告によると、現在の収益 (TTM) は $606.33M です。2023 年には $17.45M の収益があり、これは 2022 年の $25.82M と比較して 減少 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Tarsus Pharmaceuticals, Inc. の収益履歴（2018 ～ 2026）
各年末の収益
| 年 | 収益 | 変化 |
|---|---|---|
| 2026 (TTM) | $606.33M | 231.41% |
| 2024 | $182.95M | 948.62% |
| 2023 | $17.45M | -32.42% |
| 2022 | $25.82M | -54.73% |
| 2021 | $57.03M | 0.00% |
| 2020 | 0.00 | 0.00% |
| 2019 | 0.00 | 0.00% |
| 2018 | 0.00 | 0.00% |
同業他社の収益
| 企業 | 収益 | 収益の差 | 国 |
|---|---|---|---|
| $12.62B | 1,982.08% |
US
|
|
| $2.23B | 267.46% |
US
|
|
| $15.74B | 2,496.66% |
AU
|
|
| $6.02B | 893.07% |
NL
|
|
| - | - |
CH
|
